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window	 of	 the	 synthesized	 complexes.	 One	 mechanism	 of	 drug	 resistance	 via	
elevated	levels	of	glutathione	was	addressed	through	in	vitro	binding	studies	carried	
out	with	UV‐Vis	spectroscopy	and	in	vivo	glutathione	titrations	in	the	A549	cell	line.	














































































































































































































































A	 	 	 adenosine	
A549	 	 	 adenocarcinomic	human	alveolar	basal	epithelial	cells	 	 	
aq.	 	 	 aqueous		
bpy	 	 	 2,2’‐bipyridine	
bc	 	 	 2,9‐dimethyl‐4,7‐diphenyl‐1,10‐phenanthroline	
bcds	 	 	 2,9‐dimethyl‐4,7‐diphenyl‐sulfonate‐1,10‐phenanthroline	
biq	 	 	 2,2’‐biquinoline	
2,2’‐biq‐3,3’‐dca	 3,3’‐dicarboxylic	acid‐2,2’‐biquinoline	
bp	 	 	 4,7‐diphenyl‐1,10‐phenanthroline	
bpds	 	 	 4,7‐diphenyl‐sulfonate‐1,10‐phenanthroline	
C	 	 	 cytidine	
ct	 	 	 calf	thymus	
cyclobpy	 	 2‐phenyl	pyridine	
cyclophen	 	 7,8‐benzoquinoline	
cont.	 	 	 continued	
d	 	 	 doublet	
ix	
	






DNA	 	 	 deoxyribonucleic	acid	
dppz	 	 	 dipyrido[3,2‐2’,3’‐c]phenazine	
dpq	 	 	 dipyrido[3,2‐f:2’,3’‐h‐quinoxaline]	
ESI‐MS	 	 electrospray	ionization	mass	spectrometry	
G	 	 	 guanosine	
GSH	 	 	 glutathione	
HPLC	 	 	 high	pressure	liquid	chromatography	
HL60	 	 	 human	promyeloxytic	leukemia	cell	line	
8HQ	 	 	 8‐hydroxyquinoline	
IC50	 Concentration	of	a	compound	that	induces	50%	growth	
K562	 	 	 myelogenous	leukemia	cell	line	
x	
	
m	 	 	 multiplet	
MC	 	 	 metal	centered	
mmol	 	 	 millimole	
2Me8HQ	 	 2‐methyl‐8‐hydroxyquinoline	
MLCT	 	 	 metal‐to‐ligand‐charge‐transfer	
m/z	 	 	 mass	to	charge	ratio	
ML2	 	 	 myeloblastic	leukemia	cell	line	 	 	 	
NMR	 	 	 nuclear	magnetic	resonance	
PBS	 	 	 phosphate	buffered	saline	
PDT	 	 	 photodynamic	therapy	
	 	
phen	 1,10‐phenanthroline	
Pt	 	 	 platinum	
Ru	 	 	 ruthenium	
RNA	 	 	 ribonucleic	acid	
s	 	 	 singlet	
t	 	 	 triplet	
T	 	 	 thymidine	
xi	
	
TLC	 	 	 thin	layer	chromatography	
























In	 2008,	 12.7	 million	 new	 patients	 were	 diagnosed	 with	 cancer	 and	 7.6	
million	patients	died	from	cancer	related	issues.1	The	disease	does	not	discriminate	
between	 societies,	 afflicting	 economically	 developed	 and	 developing	 countries	
alike.1	 The	 term	 cancer	 applies	 to	 a	 broad	 swath	 of	 diseases	 characterized	 by	 the	
inability	 of	 an	 abnormal	 cell	 to	 regulate	 growth,	 allowing	 it	 to	 potentially	 form	
tumors.	 Disruption	 of	 the	 regulation	 of	 normal	 tumor	 suppression	 genes	 and	
activation	 of	 oncogenes	 lead	 to	 this	 abnormal	 growth	 and	 fast	 track	 the	




Combinations	 of	 the	 three	 are	 common	 based	 on	 the	 location	 of	 the	 cancer,	 risk	
factors,	 and	 potential	 for	 successful	 outcomes.4	 Chemotherapy	 involves	 the	 use	 of	
antineoplastic	drugs	to	kill	cells	that	divide	rapidly.	Current	drugs	in	the	clinic	can	
be	divided	into	categories	based	on	their	mechanism	of	action	to	prevent	replication	
of	 rogue	cells,	 and	many	cause	DNA	damage	 leading	 to	apoptosis.	Drug	categories	







to	 DNA,	 rendering	 the	 cell	 unable	 to	 undergo	 cellular	 division.	When	 DNA	 repair	
mechanisms	 fail	 to	 work,	 apoptosis	 results.12	 Cisplatin	 and	 similar	 platinum	









and	 cisplatin	 favors	 intrastrand	 binding	 of	 adjacent	 guanosines,	 but	 will	 also	
coordinate	 adenosines	 adjacent	 to	 guanosine.	 Interstrand	 complexes	 are	 lesser	





Drug	 resistance	 for	 platinum	 compound	 chemotherapy	 is	 thought	 to	 arise	
from	 many	 mechanisms,	 including	 detoxification	 by	 cellular	 sulfur‐containing	
compounds.17	 Glutathione	 is	 a	natural	 tripeptide	 found	 in	 the	 cytosol	 of	 almost	 all	
cells	in	concentrations	up	to	16	mM.18,19,20	The	sulfur	rich	compound	is	a	good	ligand	
for	 platinum	 according	 to	 Pearson’s	 hard	 soft	 acid	 base	 theory.21	 Other	 sulfur	
containing	metal	detoxification	agents	such	as	metallothionein	have	been	 found	 in	
similar	 concentrations	 in	 cisplatin‐insensitive	 cells.	 These	 detoxifying	 agents	
interfere	 with	 the	 chemotherapeutic	 role	 of	 platinum	 compounds	 and	 are	 a	
substantial	 contributor	 to	 increased	 drug	 resistance.22	 	 Several	 derivatives	 of	
cisplatin	such	as	oxaliplatin	and	carboplatin	have	been	synthesized	with	the	goal	to	
thwart	resistance,	decrease	toxicity	and	improve	activity.23	Figure	1.2	shows	several	
structures	 of	 platinum	 compounds	 that	 are	 currently	 in	 clinical	 trials	 and	
commercially	 available	 for	 therapeutic	 use.24,25	 These	 platinum	 derivatives	 work	
through	 the	 same	DNA	damage	mechanism	 and	 share	dose	 limiting	 toxicities	 and	





















metals	 including	 ruthenium,	 rhenium,	 and	 osmium	 have	 been	 investigated	 as	
possible	chemotherapeutics.33	Ruthenium	compounds	are	a	potential	alternative	to	
their	 platinum	 counterparts	 due	 to	 the	 decreased	 toxicity	 and	 variable	 oxidation	












lung	 cancer	 through	 reducing	 metastases	 weight	 without	 affecting	 the	 primary	
tumor.	 It	 is	well	 tolerated	 by	 patients	 in	 clinical	 studies.37	 KP1019	 is	 activated	 by	
reduction	 from	 RuIII	 to	 RuII	 in	 hypoxic	 tumor	 tissues	 by	 reducing	 sulfur	 rich	
biomolecules	 such	 as	 glutathione.34	 KP1019	 has	 been	 used	 in	 clinical	 trials	 for	
colorectal	cancer	and	is	also	well	tolerated	in	patients.	36		
Ruthenium	 polypyridyl	 complexes	 have	 also	 been	 investigated	 for	 their	
potential	 chemotherapeutic	 qualities.	 These	 complexes	 are	 well	 studied,	 and	
derivatives	of	 the	ruthenium	polypyridyl	complex	have	been	synthesized	to	 target	
DNA.34,38	Due	to	the	rich	synthetic	nature	of	ruthenium,	several	complexes	containing	
ligands	 with	 high	 DNA	 affinity	 have	 been	 synthesized.	 The	 groove	 binding	 and	
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metallo‐intercalating	 ability	 of	 1,10	 phenanthroline	 (phen)	 and	 dipyrido	 [3,2‐f:	 2’,	
3’‐h‐quinoxaline]	(dpq)	(see	Table	2.1)	are	well	known.39		
NAMI‐A	and	KP1019	provide	of	novel	chemotherapeutics	outside	of	cisplatin	
and	 display	 how	 transition	 metals	 can	 provide	 several	 interesting	 complex	
structures	 capable	 of	 leading	 to	 apoptosis.	 Alternatively,	 the	 DNA	 binding	
ruthenium	compounds	 in	 the	 literature	provides	 an	 alternative	 to	platinum	drugs	
with	 a	 non‐covalent	 mechanism	 of	 DNA	 interactions.	 The	 problem	with	 all	 these	
approaches,	 however,	 is	 the	 lack	of	 specificity,	 as	 these	drugs	do	not	discriminate	
between	healthy	and	cancerous	cells.		
To	 improve	 selectivity	 and	 decrease	 toxicity,	 photoactive	 complexes	 can	
increase	the	therapeutic	window	of	antitumor	drugs.		For	this	reason	photodynamic	
therapy	 (PDT)	 can	 be	 used	 to	 treat	 localized	 tumors	 with	 laser‐based	 fiber‐optic	
devices.40	 	 PDT	 is	 used	 to	 treat	 a	 variety	 of	 cancers	 accessible	with	 a	 light	 source	
including	 lung,	 superficial	 gastric,	 cervical,	 bladder,	 head,	 and	 neck.	 	 Patients	
utilizing	PDT	benefit	from	the	relatively	non‐invasiveness	of	the	treatment	that	can	
often	be	 administered	 in	 an	 outpatient	 setting.41	 	 This	 targeted	 treatment	 reduces	
the	side	effects	associated	with	traditional	chemotherapy	and	because	dose‐limiting	
toxicity	 is	 nonexistent,	 toxicity	 is	 only	 induced	 in	 the	 targeted	 tissues	when	 light	
activated.	Repeated	treatments	are	therefore	possible.		Photofrin	is	clinically	used	to	













Topical	 photosensitizers	 such	 as	 Levulan	 and	 Metvix	 are	 biosynthetic	
precursors	 to	 photofrin,	 and	 are	 used	 in	 the	 clinic	 to	 treat	 actinic	 keratosis.44	 The	
benefit	of	 these	drugs	 lies	 in	 the	mechanism	of	action.	These	catalytic	 compounds	





singlet	 oxygen	 (1O2).45	 Added	 selectivity	 arises	 from	 the	 inability	 of	 the	 highly	




therapeutics	 to	 porphyrin	 based	 photosensitizers.	 Photoactive	 octahedral	 PtIV	
complexes	 have	 been	 investigated	 due	 to	 their	 ability	 when	 light	 activated	 to	 be	
reduced	 to	 their	 cytotoxic	 PtII	 species.	 These	 complexes	 show	 better	 aqueous	
solubility	and	increased	therapeutic	indexes	with	reduced	toxicity.33	One	drawback,	
however,	 is	 the	 need	 to	 activate	 the	 PtIV	 species	 with	 high	 energy	 UV	 light.	
Polypyridyl	 ruthenium	complexes	have	also	been	 investigated	due	 to	 the	 fact	 that	
various	 structures	 can	 be	 readily	 synthesized	 and	 possess	 tunable	 absorption	
properties.47	 Long	 wavelength	 light	 is	 desired	 in	 PDT	 due	 to	 its	 increased	 tissue	
penetration.	Low	energy	transitions	that	absorb	at	longer	wavelengths	in	the	MLCT	
(metal‐to‐ligand‐charge	transfer)	region	are	an	important	attribute	in	the	design	of	
the	 metal‐based	 compounds.	 Various	 groups	 have	 developed	 several	 metal	
complexes	 that	 display	 light	 induced	 cytotoxicity	 through	 oxygen	 independent	
mechanisms.48,49		
Due	to	the	rich	nature	of	the	synthetic	chemistry	associated	with	ruthenium	







cytotoxic	 agents.	We	 aim	 to	make	 efficient	 light	 activated	 complexes	 that	 display	
high	DNA	binding,	crosslinking,	or	other	forms	of	DNA	damage,	resulting	in	toxicity	
in	cancer	cells.		The	primary	factor	considered	for	light‐activated	agents	is	the	ratio	
of	 the	 activity	 in	 light	vs.	 in	 the	dark,	which	 is	 termed	 the	phototherapeutic	 ratio.	
This	 is	 a	 direct	 measurement	 of	 the	 therapeutic	 window	 for	 PDT.	 	 Several	
compounds	have	been	synthesized,	 characterized,	and	screened	 in	cancer	cells	 for	
beneficial	anti‐tumor	behavior	 in	 this	work.	 	The	goals	defined	at	 the	onset	of	 the	
project	 included	 light‐activated	 potencies	 comparable	 to	 cisplatin,	 and	 a	 10‐fold	
phototherapeutic	 ratio,	 allowing	 for	 the	 potential	 of	 significant	 reduction	 in	 side‐
effects	in	future	clinical	applications.	The	progress	towards	achieving	these	goals	is	
described	 in	 the	 following	 chapters.	 The	 thesis	 is	 divided	 into	 the	 following	
chapters:	 Design,	 synthesis,	 in	vitro	 and	 in	vivo	 characterization	 of	 the	 complexes	













The	 photochemistry	 of	 ruthenium	 polypyridyl	 complexes	 such	 as	
[Ru(bpy)3]2+	 have	 been	 extensively	 studied.1	 The	 unique	 combination	 of	 chemical	
stability,	 redox	 properties,	 excited‐state	 reactivity,	 luminescence	 emission,	 and	
excited‐state	lifetime	of	[Ru(bpy)3]2+	and	its	derivatives	has	garnered	the	attention	
of	 researchers	 across	 multiple	 disciplines.2Ru(II)	 polypyridyl	 complexes	 play	 key	
roles	in	multiple	research	areas	such	as	photophysics,	photocatalysis,	and	electron	
and	 energy	 transfer.1The	 photochemical	 and	 photophysical	 nature	 of	 these	
compounds	is	of	interest	to	our	group	and	will	be	the	main	focus	of	this	chapter.	The	
hypothesis	of	this	project	is	that	light‐activated	Ru(II)	complexes	can	be	designed	to	
eject	 ligands	 upon	 irradiation,	 producing	 ligand	 deficient	 systems	 that	 will	 react	
with	 and	 crosslink	DNA,	 like	 cisplatin.	 The	 application	 of	 these	 systems	 is	 for	 the	
development	 of	 photo‐responsive	 chemotherapeutic	 agents.	 The	 key	 feature	 that	
controls	 this	photochemical	 reaction	 is	 intramolecular	 strain,	 generating	distorted	
Ru(II)	 complexes	 that	 undergo	 photochemical	 reactions	 with	 low	 energy,	 visible	
light.	
Unstrained	 Ru(II)	 polypyridine	 complexes	 such	 as	 [Ru(bpy)3]2+	 contain	
ligands	with		donor	orbitals	that	are	localized	on	the	nitrogen	atoms	and		donor	
and	 *	 acceptor	 orbitals	 delocalized	 on	 the	 aromatic	 rings.	 Ru(II)	 polypyridyl	
complexes	are	 typically	orange	 to	 red,	due	 to	 their	absorption	of	visible	 light.	The	
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absorption	 spectrum	 of	 [Ru(bpy)3]2+	 is	 shown	 in	 Figure	 2.1awith	 the	 electronic	
transitions	assigned.		





and	450nm	result	 from	spin	allowed	d	 to	*	 transitions.	The	 less	 intense	shoulder	
bands	at	320	and	340nm	result	from	metal‐centered	(MC),	M	to	Mtransitions.			
Figure	2.2a	shows	a	simplifiedJablonski	diagramfor	excitation	of	an	electron	
























of	 the	 3MC	state	 for	 [Ru(bpy)3]2+is	 inefficient,	producing	a	poor	quantum	yield	 for	
photodecomposition	on	 the	order	of	10‐5‐10‐2.1For	unstrained	d6	Ru(II)	 complexes	
such	 as	 [Ru(bpy)3]2+,	 population	 of	 the	 3MC	 state	 is	 inefficient	 due	 to	 the	 large	






occurs	 through	 ligand	 dissociation	 reactions	 when	 the	 3MC	 state	 is	 lowered	 in	
energy	 so	 that	 it	 can	 be	 accessed	 thermally	 from	 the	 3MLCT	 state.	 Synthesis	 of	
sterically	 strained	 ruthenium	 complexes	 decreases	 the	 3MLCT	 to	 3MC	 energy	 gap,	
allowing	population	of	the	3MC	excited	state,	resulting	in	cleavage	of	the	Ru‐N	bond.	







and	 a	 monodentate	 bipyridine	 intermediate	 with	 a	 ruthenium	 that	 is	
pentacoordinated	forms.	In	the	presence	of	excess	electron	donating	ligands	such	as	
chloride	 ions	or	 solvent	molecules,	 new	bonds	 to	 the	 ruthenium	can	 form.	At	 this	
point,	are‐coordination	process	can	occur,	reforming	the	Ru‐N	bond	or	alternatively,	
the	single	remaining	bond	to	the	bipyridine	ligand	can	be	broken,	forming	a	Ru(II)	
complex	with	 two	 chloride	 or	 two	 solvent	 ligands.	 The	 re‐coordination	process	 is	
possible	 with	 unstrained	 octahedral	 complexes	 such	 as	 [Ru(bpy)3]2+,while	 ligand	
loss	prevails	 in	 the	model	 compound	GL002,	due	 to	 the	 steric	 clash	of	 the	methyl	
groups.		
Photolabile	 model	 complexes	 with	 the	 Ru(bpy)2	 backbone	 containing	
sterically	crowding	ligands	such	as	6,6’‐dimethyl‐2,2’‐bipyridinehave	been	prepared	





tuned	 through	 the	 choice	 of	 ligands.	 The	 complex	 GL002	 has	 fast	 photoejection	
kinetics	 (t1/2=1.9	minutes,	 see	 Table	 3.1)	 due	 to	 the	 free	 rotation	 about	 the	 2,2’‐
15	
	
carbon‐carbon	 bond	 of	 6,6’‐dimethyl‐2,2’‐bipyridine.	 In	 contrast,	 addition	 of	 rigid	
ligands	to	the	Ru(bpy)2backbone	slows	the	ejection	process.	For	example,	when	the	
2,9’‐dimethyl‐1,10‐phenanthroline	 ligand	 is	 incorporated(see	 GL007,	 Figure	 2.5),	
at1/2	 of	 112.8minutes	 is	 obtained,	 as	 shown	 in	 Table	 3.1.	 This	 is	 attributed	 to	 the	
ligands’	ability	to	re‐coordinate	the	metal,	due	to	its	rigid	chelating	structure.		
The	DNA	affinity	of	the	complexes	can	also	be	tuned	through	the	addition	of	
intercalating	 ligands	 such	 as	 dpq	 (dipyrido[3,2‐f:2’,3’‐h‐quinoxaline])	 and	 dppz	
(dipyrid0[3,2‐2',3'‐c]phenazine)	(see	Table	2.1).	These	planar	ligands	are	known	to	
intercalate	 into	 the	base	 stack	of	DNA.3	 Complexes	GL003,	 009,	 010,	 021	 and	039	
were	synthesized	to	test	if	photoejecting	complexes	with	DNA	intercalating	ligands	
are	more	 potent	 than	 compounds	with	 lower	DNA	 affinity.	 Unstrained	 complexes	
GL009	and	021	contain	dpq	and	dppz	ligands	that	display	bindingto	pUC19	DNAin	
vitro,	 as	 discussed	 in	Chapter	4.	 The	photoejectable	 analogues	of	 these	 complexes	
GL003,	 010,	 and	 039	were	 synthesized	 to	 explore	 their	 biological	 activity	 in	vitro	
and	in	vivo.		
Complexes	with	different	overall	charge	states	and	alterative	backbones	have	










to	 be	 cytotoxic.4These	 complexes	 were	 designed	 to	 test	 the	 hypothesis	 that	
complexes	 could	 be	 generated	 that	 would	 create	 two	 active	 species	 –	 the	 ligand	
deficient	 Ru(II)	 complex,	 and	 the	 liberated	 ligand.	 Studies	 have	 shown	 that	
hydroxyquinoline	and	its	derivatives	have	anti‐proliferative	and	cytotoxic	effects	in	
leukemia	 cells	 lines.5	 They	 inhibit	 RNA	 synthesis	 in	 E.	 coli	 bacteria	 and	 iron	
complexes	 containing	 these	 ligands	 have	 been	 shown	 to	 be	 effective	 in	 the	U937,	
K562,	ML2,	 and	HL60	cell	 lines.6	 In	addition,	hydroxyquinoline	derivatives	 chelate	
copper,	and	acts	as	angiogenesis and proteasome inhibitors in prostate cancer cell lines.7	
An	 effort	 has	 been	 made	 to	 produce	 ruthenium	 complexes	 that	 absorb	 at	
longer	wavelengths,	as	longer	wavelength	(lower	energy)	light	can	penetrate	deeper	
into	 tissues.	 Thiswould	 provide	 access	 to	 tumors	 previously	 unreachable	 via	
photodynamic	 therapy.	 Addition	 of	 the	 biquinoline	 (biq)	 ligand	 to	 the	 Ru(phen)2	
backbone	 (see	 Table	 2.2)	 produces	 a	 60	 nm	 red	 shift	 in	 the	 UV/Vis	 profile	 of	
complex	 GL011	 (see	 Figure	 3.2).	 Alternatively,	 cyclometallating	 ligands	 2‐
phenylpyridine	 and	 7,8‐benzoquinoline	 coupled	 with	 the	 Ru(bpy)2	 backbone	
produced	complexes	GL034	and	035	(see	Table	2.2).These	cyclometallated	systems	





of	 these	 systems	 should	 be	 synthesized	 to	 determine	 their	 in	 vitro	 and	 in	 vivo	
properties.	 Finally, oxygen containing hydroxyquinoline ligands also act to lower the 
energy of the MLCT excited state, potentially red-shifting the absorption of the 
complexes further into the PDT therapeutic window. Derivatives of complexes 
containing the backbones presented in this work with different quinolines should be 







complexes	 and	 theirin	 vitroactivities	 with	 pUC19	 DNA	 (Chapter	 4)	 and	 in	
vivopotencies	 in	 the	 A549	 cell	 line	 (Chapter	 5).	 	 Complexes	 that	 produce	 an	
activated	 species	 upon	 exposure	 to	 light	were	 prepared	 to	 observe	 differences	 in	
light	and	dark	activity	with	DNA.		
The	general	preparation	of	these	complexes	begins	with	the	synthesis	ofthe	
ligands	used	 (Figure	2.4)	 and	 then	generating	 the	Ru(L)2Cl2	 starting	material	 (see	
Figure	 2.5).	 	 The	 synthetic	 nature	 of	 ruthenium	 (see	 Chapter	 1)	 allows	 efficient	
combinatorial	design.	Mono	ligands	ejected	from	synthesized	complexes	upon	light	
activation	that	show	toxicity	can	be	incorporated	into	the	bis‐Ru	backbone	resulting	





















	 A	 solution	 of	 RuCl3	 (3.8	 mmol,	 1	 g),	 free	 ligand	 L	 (7.6mmol,	 variable	 g)	
LiCl(57	mmol,	2.4	g)	and	ascorbic	acid	(4.2	mmol,	0.74	g)	were	added	to	25	mL	dry	
DMF	and	refluxed	at	150oC	for	12	hours.	The	solution	was	allowed	to	cool	to	room	





A	 solution	of	 0.38mmol	Ru(L)2Cl2	(0.1	 g)	 and	0.42	mmol	L’(variable	 g)	was	
added	to	4	mL	ethylene	glycol	in	a	pressure	tube	and	heated	at	150	oC	for	~4	hours.	
The	 solution	 was	 allowed	 to	 cool	 and	 poured	 into	 50	 mL	 of	 dH2O.	 	 A	 saturated	








ethanol	and	refluxed	at	100	 oC	 for	4	hours.	The	solution	was	poured	 into	~50	mL	
dH2O	 and	 the	 excess	 ligand	was	 extracted	with	methylene	 chloride.	 Saturated	aq.	
KPF6	was	added	and	the	PF6	salt	was	extracted	in	methylene	chloride.	The	layer	was	
dried	over	magnesium	sulfate,	filtered	and	concentrated	under	reduced	pressure.	A	
bright,	 emissive	 spot	 observed	 using	 TLC	 conditions	 described	 above	 is	 evidence	
that	the	unstrained	complex	has	formed	(see	Figure	2.2a).	Similar	purification	of	the	
complexes	 was	 carried	 out	 using	 flash	 chromatography.	 Complexes	 were	 loaded	
onto	 the	 column	 in	 acetonitrile	 and	 eluted	 with	 a	 ramping	 gradient	 of	 0.1%	
saturated	KNO3/20%H2O/80%MeCN.	The	synthesized	complexes	 typically	elute	at	
9%	dH2O.	Solvent	was	removed	under	reduced	pressure	and	reconstituted	in	25	mL	




Saturated	 tetra‐n‐butyl	 ammonium	chloride	 (1	 g	 in	5	mL	dry	 acetone)	was	
added	 to	 the	 PF6 complex salts dissolved in minimal acetone. The resulting 
precipitate was filtered in a long stem hersch funnel packed with glass wool. The 
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precipitate was washed with acetone and eluted with acetonitrile. The solvent 




H2SO4:	 HNO3(40/20	mL	 respectively)	 were	 added	 dropwise	 to	 the	 flask.	 Caution:	









dried	 over	 magnesium	 sulfate	 producing	 a	 clear	 yellow	 solution	 that	 was	
concentrated	 using	 rotary	 evaporation	 and	 dried	 under	 vacuum.	 The	 methylated	







	 Caution:	 Phendione	 is	 a	 flocculent	 solid	 and	 is	 a	mucous	 irritant.	To	 reduce	
exposure,	tare	the	reaction	flask	and	transfer	the	material	in	the	fume	hood.	1	g	(47.5	
mmol)	phendione	and	350	mL	ethanol	were	added	to	a	500	mL	round	bottom	flask.	
0.49	 mL	 (d=0.899	 gcm‐3,71	 mmol)1,2‐diaminoethane	 was	 added	 to	 the	 flask	
(solution	 golden	 brown)	 and	 heated	 at	 40	 oC	 for	 2	 hours.	 The	 reaction	 was	




The	 dimethyl	 analogue	 of	 this	 ligand	was	 prepared	 in	 a	 similar	method	 using	 the	
dmphendione	starting	material	with	similar	yields.		
Synthesis	of	dipyrid0[3,2‐~:2',3'‐c]phenazine	(dppz):13‐14	
	 1	 g	 (47.5	 mmol)	 phendione	 and	 0.77	 g	 (71	 mmol)	 1,2‐phenylene‐diamine	
were	added	 to	 a	120mL	pressure	 tube	with	1:2	EtOH:	dH2O	 (30	mL:	60	mL).	The	
pressure	tube	was	placed	in	an	oil	bath	at	180oC	and	stirred	for	3	hours	producing	a	


































Complexes	 GL005,	 GL008,	 and	 GL013	 are	 sulfonate	 or	 carboxylate	 containing	





6H),	7.62	(d,	 J=5.31	Hz,	2H),	7.46	(td,	 J=5.86,	1.65	Hz,	2H),	7.29	(d,	 J=6.59	Hz,	2H),	
7.21	 (td,	 J=7.32,	 1.47	 Hz,	 2H),	 2.14	 (s,	 6H).	 13C	 NMR	 (CD3CN):	 	 166.69,	 159.91,	
158.68,	 158.44,	 154.06,	 152.90,	 139.22,	 138.85,	 138.81,	 129.18,	 128.49,	 128.29,	








(t,	 J	 =	6.68,	4H),	2.19	 (s,	6H).	 13C	NMR	(CD3CN):		 169.63,	158.65,	158.52,	154.14,	








2H).	 13C	 NMR	 (CD3CN):	 157.23,	 157.02,	 151.96,	 151.65,	 151.61,	 147.49,	 137.47,	
137.36,	 136.55,	 130.75,	 127.81,	 126.97,	 126.93,	 126.93,	 126.80,	 125.46,	 123.88,	
123.82.	Additional	13C	peaks	due	to	concentration	dependent	molecular	aggregation	







7.26	 (s,	2H),	2.47	 (s,	6H).	 13C	NMR	(CD3CN):		 148.28,	158.159,	158.053,	153.081,	









7.34	 (td,	 J	 =	 9.0,	 1.4	 Hz,	 2H),	 7.31	 (td,	 J	 =	 9.0,	 1.4	 Hz,	 2H),	 2.0	 (s,	 6H).	 13C	 NMR	
(CD3CN):		167.50,	158.75,	158.4,	1554.01,	153.96,	152.82,	152.86,	150.53,	150.34,	
138.90,	 138.74,	 136.87,	 130.79,	 130.62,	 130.14,	 128.94,	 1218.86,	 128.53,	 128.48,	
128.41,	 128.34,	 125.87,	 125.59,	 125.49,	 26.49.16ESI	 MS	 calcd	 for	 C34H28N6Ru	 [M]‐
+622.14,	 found	 [M]+621.2,	 [M]2+311.1.	 Purity	 by	 HPLC:	 99.9%	 by	 area.	 UV/Vis	
(MeCN)	ε:287	nm	(60200),	452	(12800).		
Ru(bpy)2bcds,	GL008:	

















169.73,	 158.67,	 158.50,	 154.12,	 152.99,	 152.67,	 143.97,	 140.32,	 139.08,	 138.89,	
135.25,	133.23,	130.57,	129.63,	129.50,	128.60,	128.50,	125.66,	125.55,	26.48.	ESI	
MS	calcd	for	C40H30N8Ru	[M]+724.16,	[M]2+	362.1	found	[M]+723.3,	[M]2+362.1.Purity	







7.9,	 0.9	 Hz,	 2H),	 7.11	 (d,	 J	 =	 8.8	 Hz,	 2H),	 7.05‐7.01	 (m,	 2H).	 13C	 NMR	 (CD3CN):	 	
161.95,	 1588.69,	 154.08,	 152.15,	 149.24,	 148.54,	 140.36,	 138.49,	 138.29,	 132.36,	












Hz,	 2H),	 2.01	 (s,	 6H).	 13C	NMR	 (CD3CN):	 167.48,	 158.73,	 158.47,	 153.96,	 152.86,	
150.51,	 150.33,	 138.89,	 138.72,	 136.85,	 130.77,	 130.62,	 130.12,	 128.88,	 128.51,	
128.43,	 128.35,	 125.86,	 125.56,	 125.47,	 26.47.16ESI	 MS	 calcd	 for	 C46H36N6Ru	 [M]‐







167.43,	 166.80,	 160.28,	 160.27,	 152.13,	 152.05,	 151.35,	 151.19,	 149.95,	 149.53,	













160.31,	 160.28,	 160.25,	 160.25,	 160.24,	 154.79,	 151.79,	 151.72,	 146.52,	 137.94,	
136.66,	 136.55,	 136.21,	 135.77,	 130.33,	 130.21,	 129.97,	 129.90,	 129.85,	 129.13,	







NMR	 (CD3CN):	 	 158.86,	 158.61,	 155.34,	 153.75,	 153.70,	 153.64,	 153.61,	 150.89,	










2H),	 2.16	 (s,	 12H).	 13C	 NMR	 (CD3CN):	 	 169.68,	 167.74,	 158.96,	 153.04,	 150.42,	







(m,	 6H),	 7.46‐7.44	 (m,	 6H),	 7.32‐7.28	 (m,	 4H),	 2.02	 (s,	 12H).	 13C	NMR	 (CD3CN):		
168.72,	 166.96,	 152.53,	 149.46,	 149.19,	 148.95,	 148.32,	 137.96,	 136.74,	 135.29,	
130.19,	 129.98,	 129.74,	 129.72,	 129.06,	 128.30,	 127.43,	 127.31,	 127.28,	 126.59,	
125.89,	 125.27,	 26.14,	 24.84.	 ESI	MS	 calcd	 for	 C52H41N6Ru	 [M]+851.24,	 found	 [M]‐







8.4	 Hz,	 2H),	 7.38‐7.33	 (m,	 5H),	 7.22	 (d,	 J	 =	 8.2	 Hz,	 2H),	 2.16	 (s,	 12H).	 13C	 NMR	
(CD3CN):		169.81,	167.92,	154.09,	140.52,	149.37,	149.34,	139.01,	138.20,	137.63,	
131.00,	129.01,	128.51,	128.29,	128.23,	127.52,	126.17,	26.88,	25.88.16	ESI	MS	calcd	
































































































































































HPLC	 equipped	with	 a	model	 G1311A	 quaternary	 pump,	 G1315B	UV	 diode	 array	
detector	 and	 Chemstation	 software	 version	 B.01.03.	 Chromatographic	 conditions	
were	optimized	on	a	Column	Technologies	Inc.	C18,	120	Å	(250	mm	x	4.6	mm	inner	
diameter,	5	μm)	fitted	with	a	Phenomenex	C18	(4	mm	x	3	mm)	guard	column.	The	




















	Successful	 PDT	 complexes	 should	 efficiently	 produce	 the	 desired	 active	
species	upon	light	activation,	but	not	react	so	quickly	under	ambient	light	conditions	
as	 to	 inhibit	 administration	 of	 the	 drug.	 Moderate	 light	 stability	 is	 required	 to	
ensure	 that	 the	 product	 can	 be	 efficiently	 handled	 and	 transferred	 by	 medical	
personnel	 to	 the	 patient,	 and	 upon	 light	 activation,	 provide	 the	 desired	 cytotoxic	
product.	However,	the	complexes	have	to	react	sufficiently	quickly	for	the	patient	to	
get	an	appropriate	 light	dose	 in	a	short	 time	 to	be	medically	useful.	Photoejection	
experiments	 of	 the	 complexes	 were	 monitored	 by	 UV‐Vis	 to	 observe	 the	 rate	 of	




Ruthenium	complexes	 that	are	not	 sterically	 strained	do	not	exhibit	photo‐
degradation	 due	 to	 the	 low	 efficiency	 of	 population	 of	 the	 3MC	 excited	 state	 after	
photoexcitation	 at	 room	 or	 physiological	 temperatures	 (22	 or	 37	 ˚C).	 	 These	
compounds	are	stable	 in	 the	presence	of	 light.	Several	unstrained	complexes	were	
synthesized	to	act	as	control	compounds.	Alternatively,	several	strained	complexes	





UV‐Vis	 spectroscopy	was	used	 to	observe	 the	absorbance	properties	of	 the	
synthesized	 ruthenium	 complexes.	 Due	 to	 the	 number	 of	 complexes	 analyzed	 for	
this	study,	all	absorption	profile	figures	are	included	at	the	end	of	the	chapter.		
	 Figure	3.1	shows	the	typical	absorbance	spectra	of	ruthenium	complexes	that	
are	 stable	 in	 the	 presence	 of	 light.	 Complexes	 GL004,	 009,	 and	 021	 display	 an	
absorbance	maximum	at	~450	nm,	and	the	absorption	spectra	do	not	change	upon	
exposure	to	light.		
In	 contrast,	 sterically	 hindered,	 octahedral	 ruthenium	 complexes	 can	
successfully	 shuttle	 electrons	 into	 the	 3MC	 excited	 state	with	 blue	 light	 activation	
(see	Figure	2.2).	Exposure	to	blue	light	was	punctuated	by	periodic	UV‐Vis	scans	in	
order	 to	 track	 the	 conversion	 of	 the	 starting	 complex	 to	 the	 photoproduct.	 	 The	
difference	 in	absorbance	at	~495	nm	vs	~410	nm	(A495‐410)	were	plotted	against	











ejection	 profiles.	 For	 example,	 GL007	 has	 a	 half‐life	 of	 112.8	minutes,	 ~60	 times	
slower	 than	GL002	(see	Table	3.1).	GL007	does	not	 incorporate	 the	6,6’‐dimethyl‐
2,2’‐bipyridine	 ligand;	 instead,	 it	 contains	 2,9‐dimethyl‐1,10‐phenanthroline	 (see	
Table	 2.1).	 An	 apparent	 trend	 is	 that	 complexes	 utilizing	 the	 6,6’‐dimethyl‐2,2’‐
bipyridine	 ligand	 tend	 to	 degrade	 faster	 than	 fused	 ring	 systems	 such	 as	 1,10‐
phenanthroline.	 Increasing	 the	 planar	 surface	 in	 the	 fused	 ligands	 by	 adding	 a	
dmdpq	(complex	GL003)	or	dmdppz	(complex	GL010)	ligand	(see	Table	2.1)	to	the	
Ru(bpy)2	 scaffold	 further	 supports	 this	 observation.	 GL003	 has	 a	 long	 half‐life	 of	
60.9	minutes,	and	GL010	has	a	half‐life	greater	than	6	hours.	In	order	to	obtain	an	
ejection	 profile	 for	 GL010,	 intense	white	 light	was	 employed	 instead	 of	 blue	 light	
used	 in	 other	 studies.	 Under	 these	 conditions,	 the	 half‐life	 of	 the	 complex	 is	 20.5	
minutes	(see	Table	3.1).		




dmdppz	 (see	 Table	 2.1)	 appears	 to	 occur	 readily,	 hindering	 the	 complete	 photo‐
dissociation	 of	 the	 ligand	 and	 resulting	 in	 longer	 half	 lives	 (see	 Table	 3.1).	 The	






fastest	 ejecting	 complexes	 are	 the	 ones	 utilizing	 the	 2,2’‐6,6’‐dimethyl‐bipyridine	
ligand.	Complex	GL002	and	005	have	half‐lives	of	1.9	and	0.6	minutes	respectively.	
Moving	the	methyl	group	around	the	bipyridine	ligand	to	the	3,3’	positions	provides	
a	 different	 type	 of	 steric	 clash	 (“backside	 clash”)	 seen	 in	 complex	 GL006,	
significantly	increasing	the	t1/2	to	230	minutes.		






To	 observe	 the	 effect	 of	 electron	withdrawing	 groups	 on	 ejection	 kinetics,	
GL008	 and	 014	 were	 synthesized.	 Both	 compounds	 contain	 the	 same	 Ru(bpy)2	
backbone	and	only	differ	by	the	addition	of	sulfonate	groups	to	complex	GL008	(see	
Table	2.2).	A	six‐fold	increase	 in	the	ejection	kinetics	was	observed	for	GL008	and	
014,	 with	 t1/2	 values	 of	 12.6	 and	 59.7	 minutes	 respectively	 (see	 Table	 3.1).	 The	
addition	of	 these	 groups	may	have	 a	negative	 effect	 on	 the	 ability	of	 the	nitrogen	
atoms	 to	 efficiently	 donate	 their	 electrons	 to	 the	 ruthenium	 center	 and	 could	 be	
another	mechanism	by	which	the	ejection	kinetics	can	be	tuned.	
However,	 addition	 of	 electron	 withdrawing	 carboxylic	 acid	 groups	 to	 the	




the	 4,4’	 positions	 and	 displays	 the	 slowest	 ejection	 kinetics	 observed	 under	 blue	
light,	with	a	 t1/2	of	greater	 than	six	hours	(see	Table	3.1).	 	 Intense	white	 light	was	




same	 bis‐1,10‐phenanthroline	 backbone	 containing	 ligands	 such	 as	 6,6’‐dimethyl‐
2,2’‐bipyridine	 with	 carboxylic	 acid	 groups	 at	 the	 4,4’	 position	 should	 be	
synthesized	 to	 understand	 why	 complex	 GL011	 has	 faster	 ejection	 kinetics	 than	
GL013.		
The	 addition	of	 4,7‐diphenyl	 groups	 to	 the	1,10‐phenanthroline	 ligand	also	
appears	to	hinder	dissociation.		A	three	fold	kinetic	difference	(5.4	and	15.2	minutes	
respectively)	 is	observed	 in	the	half‐lives	of	GL022	and	023.	 It	 is	possible	 that	 the	
addition	 of	 the	 para‐electron	 donating	 phenyl	 groups	 stabilize	 the	 nitrogen‐
ruthenium	bond,	hindering	photo‐dissociation.	The	6,6‐dimethyl‐4,7‐diphenyl‐2,2’‐
bipyridine	analogue	containing	complexes	that	contain	the	electron	donating	phenyl	








methyl	 group	 at	 the	 two‐position	 on	 the	 quinoline	 ligand.	 Modeling	 may	 be	
necessary	 to	understand	why	GL018	ejects	 faster,	and	produces	a	mix	of	products	
(see	 Table	 3.2)	 as	 opposed	 to	 the	 more	 sterically	 hindered	 GL019,	 which	 ejects	
slower	and	produces	one	photo‐dissociation	product.		
Very	 reactive	 complexes	 containing	 two	 sterically	hindered	 ligands	 such	as	
the	Ru(dmbpy)2	starting	material	with	2,2’‐bipyridine	as	well	as	the	slower	ejecting	
dmdpq	ligand	were	synthesized.	Products	of	these	reactions	were	confirmed	by	the	
absence	 of	 an	 emissive	 spot	 on	 thin	 layer	 chromatography	 and	 by	 mass	
spectrometry	 of	 the	 reaction	mixture,	 but	 the	 compounds	 readily	 degraded	 upon	
flash	 chromatography	 purification	 and	 were	 unable	 to	 be	 characterized.	 This	
showed	 that	 the	Ru(dmbpy)2	backbone	 is	 too	 reactive	 for	 the	generation	of	useful	
complexes	for	PDT	applications.	
In	order	to	tune	the	absorption	profiles	of	 the	metal	complexes,	a	synthetic	
approach	was	attempted	 to	generate	 complexes	 that	absorb	closer	 to	 the	 infrared	
region	 of	 the	 spectrum.	 Compounds	 that	 readily	 degrade	 to	 their	 corresponding	
activated	 species	 utilizing	 longer	 wavelength	 light	 are	 desirable	 as	 the	 longer	
wavelength	light	is	capable	of	penetrating	deeper	tissues.	The	Ru(phen)2Cl2	scaffold	






GL011.	 The	 strain	 from	 the	 additional	 ring	 on	 the	 biquinoline	 ligand	 produces	 a	
photoejecting	complex	(see	Table	3.2).			
The	desired	red	shift	was	also	observed	utilizing	the	cyclometallated	ligands	
2‐phenylpyridine	 and	 7,8‐benzoquinoline	 coupled	 with	 the	 Ru(bpy)2	 backbone	
shown	 in	 complexes	 GL034	 and	 035	 (Figure	 3.1)	 Cyclometallated	 systems	 GL034	
and	 035	 are	 significantly	 red	 shifted,	 as	 expected,	 with	 observed	 absorbance	



































































Table 3.1:  Complex t1/2 values 
Complex Code Complex t1/2 (minutes) 
GL002 Ru(bpy)2dmbpy 1.9 
GL003 Ru(bpy)2dmdpq 60.9 
GL005 Ru(bpds)2dmbpy 0.6 
GL006 Ru(bpy)2-3,3’dmbpy 230 
GL007 Ru(bpy)2dmphen 112.8 
GL008 Ru(bpy)2bcds 12.6 
GL010 Ru(bpy)2dmdppz >6hrs/20.5* 
GL011 Ru(phen)2biq 89.2 
GL013 Ru(bpy)2-2,2’biq-4,4’-dca >8hrs/242.3* 
GL014 Ru(bpy)2bc 59.7 
GL018 Ru(dmphen)2-8HQ 17.3 
GL019 Ru(dmphen)2-8H-2MeQ 32.7 
GL022 Ru(dmphen)2bpy 5.4 
GL023 Ru(dmphen)2bp 15.2 
GL039 Ru(dmphen)2dpq 3.2 






Mass	 spec	 experiments	 were	 carried	 out	 to	 determine	 the	 identity	 of	 the	





species	and	ejected	 ligand	masses	were	observed	post‐exposure.	 	As	some	 ligands	
are	 observed	 better	 than	 others	 on	 the	 instrument,	 only	 qualitative	 observations	
were	 made	 about	 the	 percent	 abundance	 of	 the	 ejected	 ligands.	 For	 quantitative	
measurements	of	reaction	kinetics,	see	Table	3.1.		
Infusion	 of	 the	 model	 complex	 GL002	 in	 the	 absence	 of	 light	 gives	 the	
expected	masses	 of	 the	 complex	 (M+	=	 743	 and	M2+	=	 299).	 Following	white	 light	
activation,	 infusion	 of	 the	 same	 sample	 gives	 the	 expected,	 ejected	 ligand	 6,6’‐
dimethyl‐2,2’‐bipyridine	(m/z	=	185.0	amu)	as	well	as	the	activated	Ru(bpy)2	(m/z	
=	414)	 species	 capable	of	 cross‐linking	DNA.	The	half‐life	of	GL002	 is	1.9	minutes	
(see	 Table	 3.1)	 and	 complete	 conversion	 of	 reactant	 to	 product	 is	 qualitatively	
observed.	
Complexes	with	 the	 same	Ru(bpy)2	 scaffold	 such	 as	 GL003,	 006,	 007,	 010,	
and	 014	 exhibit	 similar	 ejection	 profiles,	 producing	 the	 more	 sterically	 hindered	




2.1),	 resulting	 in	 incomplete	 product	 conversion	with	 two	minutes	 of	 white	 light	
photo‐activation.		
Utilizing	 the	 more	 rigid	 bis‐1,10‐phenathroline	 (m/z	 =	 462)	 backbone	
similarly	yields	the	ejection	of	the	single	biquinoline	ligand	(m/z	=	257)	observed	in	
complex	GL011.		Addition	of	methyl	groups	to	this	more	rigid	backbone	such	as	the	
Ru(bis‐2,9‐dimethyl‐1,10‐phenanthroline)2	 scaffold	displayed	 in	 complexes	GL018,	
019,	 022,	 023,	 and	 039,	 produce	 different	 active	 species.	 GL018	 and	 022	 give	 a	
mixture	of	activated	products	when	exposed	to	light.		Complex	GL018	ejects	the	2,9‐
dimethyl‐1,10‐phenanthroline	 (m/z	 =	 209)	 and	 8‐hydroxyquinoline	 (m/z	 =	 146)	
ligands.	 	Similarly,	complex	GL021	ejects	2,9‐dimethyl‐1,10‐phenanthroline	(m/z	=	
209)	as	well	as	2,2’‐bipyridine	(m/z	=	157).	How	this	mixture	of	activated	products	




ejects	 a	mixture	 of	 products,	 GL019	 only	 ejects	 the	 quinoline	 ligand	 (m/z	 =	 160).	
These	 complexes	 have	 similar	 in	vitro	 IC50	results	 (31	 μM,	 see	 Table	 4.1)	 forming	























GL002	 Ru(bpy)2dmbpy	 dmbpy	 100	
GL003	 Ru(bpy)2dmdpq	 dmdpq	 60	
GL005	 Ru(bpds)2dmbpy	 dmbpy	 100	
GL006	 Ru(bpy)2‐3,3’dmbpy	 3,3’dmbpy	 60	




GL010	 Ru(bpy)2dmdppz	 dmdppq	 90	




GL014	 Ru(bpy)2bc	 bc	 40	
GL018	 Ru(dmphen)28HQ	 8HQ/dmphen	 60	
GL019	 Ru(dmphen)2‐2‐Me‐8HQ	 2MeHQ	 50	
GL022	 Ru(dmphen)2bpy	 bpy/dmphen	 80	
GL023	 Ru(dmphen)2bp	 dmphen	 50	









N7	 positions	 of	 adenosine	 as	 well	 as	 the	 N3	 position	 of	 cytidine.2	 Cisplatin	 has	
limited	 to	 no	 reactivity	with	 thymidine.3	To	 determine	which	 bases	 GL002	 reacts	
with,	a	2:1	ratio	of	GL002:	individual	nucleosides	(guanosine,	adenosine,	cytidine,	or	
thymidine)	 were	 studied	 via	 ESI‐MS.	 Dark	 control	 experiments	 were	 ran	 parallel	
with	light	activated	samples	and	incubated	for	one	hour	before	MS	analysis.	All	dark	
control	samples	displayed	similar	results.	Masses	of	GL002	(M+	m/z	=	597,	M2+	m/z	
=	 298)	 were	 observed	 in	 all	 samples	 with	 the	 individual	 nucleoside	 masses	
(adenosine	m/z	=	268,	thymidine	m/z	=	242,	cytidine	m/z	=	242,	guanosine	m/z	=	
284).	 Infusion	of	 light	activated	 reactions	yielded	 complexes	with	all	 of	 the	bases,	
though	 to	 a	 much	 lesser	 extent	 with	 thymidine.	 The	masses	 observed	 for	 photo‐
activated	GL002	are	the	active	species,	Ru(bpy)2	(m/z	=	414)	and	the	ejected	ligand	
dmbpy	(m/z	=	185).	Reactions	with	adenosine	and	photo‐activated	GL002	rendered	
a	 complex	masses	 of	m/z	=	 680	 (expected	m/z	=	 681),	which	 corresponds	 to	 the	
Ru(bpy)2	 (m/z	 =	 414)	 active	 species	 plus	 adenosine	 (m/z	 =	 268).	 The	 GL002‐
thymidine	complex	was	found	at	very	 low	abundance	(m/z	=	655,	expected	m/z	=	












μM	 per	 base	 and	 injected	 to	 serve	 as	 a	 standard	 and	 to	 calculate	 the	 percent	
recovery	of	 the	 individual	bases	 (see	Figure	3.3).	Retention	 times	observed	of	 the	
injected	bases	are:	Cytidine,	13.8	minutes;	Adenosine,	19	minutes;	Guanosine,	19.8	
minutes;	 Thymidine,	 22.1	minutes	 (the	 slight	 shift	 in	 retention	 times	 of	 the	bases	
observed	 upon	 the	 addition	 of	 GL002	 in	 Figure	 3.3b	 is	 due	 to	 inefficient	
equilibration	of	the	column	prior	to	injection.	The	method	should	be	extended	to	60	
minutes,	 returning	 the	 gradient	 to	5%	B	 at	 55	minutes	 to	 allow	adequate	 column	
requilibration	 prior	 to	 subsequent	 injections.	 Complex	 masses	 similar	 to	 those	
found	above	were	observed	with	all	nucleosides	in	low	abundance.	Addition	of	the	
peak	 at	 RT	 =	 22.8	minutes	 contains	 the	mass	 of	 the	 active	 species	 Ru(bpy)2	 plus	
guanosine	(m/z	=	696)	is	displayed	in	Figure	3.3c.	Percent	recovery	was	calculated	















experiment	was	performed	while	 flowing	sample	 into	 the	spectrometer.	This	 light	




185	 ion	 corresponds	 to	 the	 ejected	 6,6’‐dimethyl‐2,2’‐bipyridine	 ligand.	 The	
isosbestic	point	observed	at	~1.5	minutes	parallels	 the	half‐life	observed	 in	Table	








Absorbance	 measurements	 were	 obtained	 using	 an	 Agilent	 8353	 UV‐Vis	
Spectrophotometer	 equipped	 with	 Agilent	 Chemstation	 Version	 B.02.01	 sp1	
software	using	a	1	cm	cuvette.	The	instrument	was	blanked	on	the	solvent	used	in	
the	 specific	 experiment.	Compound	 concentrations	were	 ca.	30	μM,	 and	 the	 initial	
dark	 control	 was	 scanned	 followed	 by	 exposure	 to	 blue	 light	 with	 Dell	 1410X	
projector/200	W	light	source.	Samples	were	placed	12	inches	from	the	light	source.		








Micromolar	 solutions	 of	 each	 complex	 were	 infused	 in	 80:20:0.1%	
methanol:water:formic	acid	before	and	after	two	minute	light	exposure	with	a	410	








DMSO	 solutions	 of	 the	 individual	 nucleosides	 were	 prepared.	 Mixtures	 of	 the	
individual	 bases	 with	 GL002	 were	 prepared	 at	 1:2	 (150	 μM	 nucleoside:	 300	 μM	
GL002)	 ratios.	 Dark	 control	 samples	 were	 prepared	 through	 the	 addition	 of	 the	
nucleoside	with	 GL002	 and	 protected	 from	 light	wrapped	 in	 aluminum	 foil.	 Light	
activated	samples	were	prepared	through	the	addition	of	the	nucleoside	with	GL002	




	 Nucleosides	 used	 are	 described	 above.	 1:1	 GL002	 (1200	 μM):	 nucleoside	
(300	μM	each)	 concentrations	were	used	 to	 obtain	 the	 results.	Using	 stock	DMSO	
solutions	of	 the	nucleosides,	a	mixture	was	prepared	at	300	μM	per	base	and	was	
added	to	photo‐ejected	GL002	in	dH2O	and	allowed	to	incubate	at	37	oC	for	2	hours.	
A	 nucleoside	 only	 sample	was	 prepared	 at	 identical	 concentration	 of	 300	 μM	per	
base	 in	 dH2O	 to	 serve	 as	 a	 standard	 and	 to	 calculate	 percent	 recovery.	 A	 blank	
solution	was	prepared	to	mimic	DMSO	concentrations	in	dH2O.	The	experiment	was	
carried	 out	 with	 the	 previously	mentioned	 ESI	mass	 spectrophotometer	with	 the	
addition	of	the	two	Varian	ProStar	pump	(model	210).	10	μL	were	injected	on	a	C18	




















Micromolar	 solutions	 of	 GL002	 were	 infused	 in	 80:20:0.1%	
MeOH:dH2O:Formic	 Acid	 and	 acquired	 on	 the	 previously	 mentioned	 ESI	 mass	
spectrophotometer.	Sample	was	infused	in	the	dark	and	was	exposed	to	light	with	a	







Other	 scientists	 including	Dr.	David	Heidary	and	Erin	Wachter	 contributed	 to	 this	
this	chapter.	
Introduction	
The	 goal	 of	 this	 project	 is	 to	 synthesize	 photoactive	 complexes	 that	 form	
cross‐links	 with	 DNA,	 leading	 to	 cell	 death.	 A	 distinction	 between	 dark	 and	 light	





In	 vitro	 gel	 electrophoresis	 experiments	 were	 carried	 out	 with	 pUC19	
plasmid	 DNA	 to	 analyze	 the	 DNA	 damage	 caused	 by	 the	 synthesized	 ruthenium	
complexes	 either	 in	 the	 dark	 or	 through	 light	 activation.	 The	 activity	 of	 the	
complexes	 was	 compared	 to	 the	 chemotherapeutic	 cisplatin,	 the	 prototypical	
inorganic	 DNA	 damaging	 agent.	 Cisplatin	 cross‐links	 DNA,	 which	 results	 in	 the	
induction	 of	 cell	 death,	 but	 a	 significant	 drawback	 is	 that	 it	 does	 not	 distinguish	
between	 healthy	 and	 cancerous	 cells.1	 Unwinding	 of	 platinated	 pUC19	 DNA	 is	






the	compound	that	resulted	 in	 the	pUC19	plasmid	existing	 in	a	state	where	 it	was	




	 To	determine	 the	 type	of	DNA	 interaction	or	damage	 that	could	occur	with	
the	ruthenium	complexes,	DNA	damage	was	induced	with	other	control	compounds	
and	 agents.	 The	 metal	 complex	 copper	 phenanthroline	 (Cu(phen)2)	 is	 known	 to	
produce	 single	 strand	 breaks	 by	 nicking	 the	 DNA	 forming	 the	 relaxed	 circular	
plasmid	 DNA.2	 This	 complex	 serves	 as	 a	 standard	 for	 single	 strand	 breaks	 to	 the	
pUC19	DNA	and	 is	 included	on	all	 gels.	Alternatively,	 complexes	 that	 form	double	
strand	 breaks	 are	 highly	 desirable.	 This	 effect	 is	 included	 as	 a	 standard	 on	 gels	
through	 the	 use	 of	 the	 restriction	 enzyme	 EcoRI.3	 Severe	 damage	 to	 the	 DNA	
through	 double	 strand	 breaks	 produces	 linear	 DNA	 leading	 to	 cell	 death.	 Double	







complex	 followed	 by	 irradiation	 with	 blue	 light	 for	 one	 or	 three	 hours.	 Initial	
samples	were	pulled	before	light	activation,	and	were	protected	from	light	to	serve	
as	the	dark	control.	Due	to	the	numerous	compounds	synthesized,	this	chapter	will	





are	 included	 in	Figure	4.6.	 This	 figure	 contains	 all	 gels	 produced	by	 complexes	 in	
this	 thesis.	 These	 gels	 provide	 information	 on	 the	 types	 of	 DNA	 damage	 the	
complexes	 create	 and	 the	 concentration	 of	 the	 compound	 required	 to	 achieve	 the	













GL002		 	 	 	 	 GL003	
	 	 	











species	are	generated,	 it	 is	 surprising	 that	 the	 IC50	values	are	not	equivalent.	This	
disconnect	 is	 explained	 by	 the	 fact	 that	 GL003,	 006,	 007,	 and	 014	 are	 kinetically	
slower	 to	 produce	 the	 active	 species	 with	 t1/2	 values	 of	 62,	 >	 232,	 128,	 and	 60	
minutes	respectively	(see	Table	3.1).	This	decreased	efficiency	to	produce	the	active	




into	 the	 base	 stack	 of	 the	 DNA	 and	 the	 subsequent	 unwinding	 of	 the	 DNA.5		




associated	 with	 other	 ruthenium‐phenanthroline	 complexes.	 This	 is	 attributed	 to	
the	 generation	 of	 reactive	 oxygen	 species	 (ROS,	 see	 section	 3,	 complexes	 that	
produce	 single	 strand	DNA	breaks	with	 pUC19	DNA).	 Complex	GL014	 also	 shows	
similar	 cross‐linking	 to	GL002	 in	 addition	 to	 single	 strand	breaks	observed	 in	 the	
three	hour	gel.	The	ability	 to	bind	DNA	and	produce	single	strand	breaks	with	the	
addition	 of	 the	 bathophen	 ligand	might	 account	 for	 the	 increased	 dark	 A549	 cell	
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viability	 that	 is	 observed	 (dark	 IC50	 value	 =	 9.3	 μM,	 see	 Table	 5.5).	 Complexes	
containing	the	bis‐bathophen	backbones	should	be	synthesized	to	increase	potency.	




Complexes	 GL018,	 019,	 022,	 023,	 and	 039	 contain	 the	 Ru(dmphen)2	 backbone.	 A		
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Complexes	 GL018	 and	 019	 are	 quinoline‐containing	 complexes	 that	 cross‐
link	pUC19	DNA	with	 IC50	 values	of	30	μM	at	 three	hours.	GL019	produces	 single	











cross‐links,	 the	 complex	 also	produces	 single	 strand	breaks	 and	 intercalates	DNA.	
The	increased	DNA	affinity	stems	from	the	addition	of	the	planar	dpq	ligand	to	the	
















GL009		 	 	 	 	 GL010	
	
	
	 	These	 compounds	display	 similar	 results	 to	GL003,	where	 smearing	of	 the	
DNA	plasmid	was	observed	in	the	gels.	While	GL009	shows	no	cross‐linking	because	
it	 is	 not	 photoative,	 GL010	 can	 slowly	 produce	 the	 same	 Ru(bpy)2	 active	 species	
((t1/2	=	 >	 6	 hrs),	 see	 Table	 3.1)	 resulting	 in	 the	 observed,	 although	 slight	 cross‐
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the	 DNA.	 The	 IC50	 value	 for	 complex	 GL005	 is	 approximately	 60	 μM	 at	 the	 three	
hour	time	point	(note	that	only	about	10%	of	the	pUC19	DNA	is	converted	to	single	
strand).	Producing	 the	 active	 species	 of	GL005	 is	 kinetically,	 very	 efficient,	with	 a	
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t1/2	 of	 0.6	 minutes	 (see	 Table	 3.1).	 The	 complex	 contains	 the	 bis‐
bathophendisulfonate	backbone	to	give	an	overall	charge	of	 ‐2,	while	a	majority	of	
the	 complexes	 discussed	 in	 this	 work	 have	 an	 overall	 charge	 of	 +2.	 The	 yield	 of	
ssDNA	produced	by	GL005	is	low	compared	to	GL004.	This	is	thought	to	be	due	to	
the	 photoejection,	 which	 decreases	 the	 yield	 of	 1O2.	 There	 is	 also	 a	 decreased	




the	 decreased	 affinity	 through	 the	 negatively	 charged	 backbone.	 Additional	
complexes	with	similar	backbones	should	be	synthesized	to	prove	this	hypothesis.		
Complex	GL011	shows	efficient	cross‐linking	at	an	IC50	value	of	30	μM	with	
single	 strand	 breaks	 occurring	 at	 higher	 concentrations.	 The	Ru(phen)2	 backbone	
with	the	addition	of	a	biquinoline	ligand	shifts	the	absorbance	to	the	red	by	~60	nm	
(see	Figure	3.2).	A	phototherapeutic	ratio	of	5.4	(see	Table	5.5)	 is	observed	 in	 the	
A549	 cell	 viability	 assay.	 Similar	 derivatives	will	 be	 important	 in	 future	 research	
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GL013		 	 	 	 	 GL014	
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CT	DNA	yielded	very	 little	 change	 in	 the	 spectra	 over	24	hours	 and	 are	 shown	 in	
Figure	 4.7a.	 Figure	 4.7b	 displays	 the	 reaction	 of	 photo‐activated	 GL002	 upon	 the	
addition	of	CT	DNA,	where	scans	were	taken	over	a	period	of	seven	hours	to	provide	
the	kinetic	profile	 for	 the	reaction.	The	CT	DNA	reacts	rapidly,	as	observed	by	 the	
spectral	change	observed	in	Figure	4.7b.	A	decrease	in	absorbance	around	400	nm	
with	an	increase	absorbance	around	490	nm	is	observed.	To	determine	the	reaction	














	 Although	cisplatin	 is	 capable	of	binding	guanine,	 cytosine,	and	adenine,	 the	




Once	 the	binding	kinetics	 for	 the	 reaction	of	GL002	with	Calf	Thymus	DNA	
were	determined	(see	Figure	4.7)	and	preference	to	guanosine	was	found	through	
nucleoside	selectivity	experiments	using	LC‐MS	(see	Figure	3.3),	the	binding	kinetics	
for	 GL002	 with	 guanosine	 was	 determined	 using	 UV‐Vis	 spectroscopy.	 This	 was	
assessed	by	reacting	20	μM	GL002	with	1	mM	Guanosine	in	10	mM	NaH2PO4	buffer	
at	37	oC.		To	ensure	that	the	interaction	of	guanosine	was	mediated	by	the	activated	
GL002,	 control	 dark	 experiments	 were	 performed	 with	 unactivated	 GL002.	 The	




with	 guanosine	 as	 observed	 by	 the	 spectral	 change	 in	 Figure	 4.8b.	 Data	 was	











of	 the	most	 important	role	of	GSH	 is	detoxification	of	carcinogens,13a	and	elevated	
levels	 of	 GSH	 lead	 to	 chemotherapeutic	 drug	 resistance	 and	 aid	 in	 cell	 survival.14	













the	 metal	 only	 and	 not	 for	 a	 coordination	 complex	 with	 aromatic	 ligands,	 which	
affect	the	electron	density	of	the	metal	center.	This	experimental	results	show	that	
sulfur	 has	 a	 higher	 affinity	 for	 the	 platinum	 in	 cisplatin	 over	 ruthenium	 in	













Maxi	 Prep	 kit	 by	 Qiagen.	 Buffered	 solutions	 containing,	 tris	 base,	 and	 acetic	 acid	
were	 obtained	 from	Sigma,	 VWR	or	 Fisher	 and	were	 prepared	 to	 the	 appropriate	
concentrations	using	Glazer	Lab	Agarose	Gel	Electrophoresis	Protocols.	Ingredients	
for	 the	 DNA	 loading	 dye	 include	 bromophenol	 blue,	 xylene	 cyanol,	 and	 glyceron	
were	obtained	from	VWR	and	prepared	to	appropriate	concentrations	using	Glazer	
Laboratory	 Protocols.	 Single	 strand	 breaks	 of	 the	 plasmid	 (relaxed	 circle)	 were	
observed	 using	 copper	 phenanthroline	 (Cu(phen)2)	 obtained	 from	 Sigma	 and	
prepared	 via	 the	 reaction	 outlined	 below.	Reagent	 grade	 dithiothreitol	 (DTT)	 and	
H2O2	were	 obtained	 from	VWR.	 Double	 strand	 (linear	 DNA)	 breaks	 to	 the	 pUC19	
plasma	DNA	were	observed	using	 the	endonuclease	enzyme	EcoR1	obtained	 from	
Fisher	and	was	prepared	per	protocol	outlined	below.	A	DNA	ladder	from	Promega	
































acetate	 buffer	 and	 heated	 to	 boiling	 ensure	 complete	 dissolution	 in	 a	microwave.		




A	 dilution	 series	 was	 prepared	 in	 clear,	 96‐well	 flat	 bottom	 plates	 (clear,	
Costar)	of	the	following	ruthenium	complex	concentrations	in	10	mM	Na2PO4	buffer:	







sample	 aliquots	 with	 8	 μL	 of	 the	 samples	 being	 loaded	 into	 the	 gel	 well.	 Typical	
order	 of	 the	 loaded	 samples	 is:	 DNA	 ladder,	 EcoR1,	 Cu(OP)2,	 0	 μM	 ruthenium	
complex	 to	 500	 μM	 ruthenium	 complex,	 DNA	 ladder.	 The	 gels	 were	 run	 for	 75	
minutes	at	100	mV.	Gels	were	stained	with	7.5	μL	of	ethidium	bromide	in	150	mL	1X	





Reaction	 kinetics	 were	 obtained	 for	 GL002	 with	 Calf	 Thymus	 DNA	 in	
NaH2PO4	buffer	at	pH	7.4	at	37	oC	using	an	Agilent	8353	UV‐Vis	spectrophotometer	
equipped	with	Chemstation	B.02.01	 software	and	a	 temperature	 controller	peltier	
(Agilent	89090A).		Calf	thymus	DNA	was	obtained	from	ATCC	and	sonicated	for	30	
minutes	to	produce	uniform	breaks	in	the	DNA.		The	instrument	was	blanked	on	7	
μL	 of	 1M	NaH2PO4	 at	 pH	 7.4	 (10	mM)	 and	 691	 μL	 of	 deionized	water	 in	 a	 small	
volume	cuvette.	2.1	μL	of	GL002	(6.55	mM)	was	added	to	the	blank	solution	to	give	
002:	 NaH2PO4	 concentrations	 of	 20	 μM:	 10	mM	 respectively.	 Following	 an	 initial	
scan,	the	cuvette	was	placed	under	the	Dell	projector	(see	Chapter	3.1)	and	exposed	
to	 blue	 light	 until	 no	 change	 was	 observed	 in	 the	 UV	 spectra	 confirming	 the	
complete	 conversion	 of	 the	 complex	 to	 the	 Ru(bpy)2	 active	 species..	 The	 reaction	
was	initiated	through	the	addition	of	5.8	μL	sonicated	calf	thymus	DNA	(5160	μM	in	
base	 pairs)	 to	 294.2	 μL	 of	 the	 compound/buffer	 solution	 above	 to	 give	 the	 final	
002:CT	DNA:	NaH2PO4	concentrations	of	19.6	μM:	100	μM:	9.8	mM	respectively.	The	
cuvette	was	placed	in	the	sample	holder	with	the	peltier	temperature	controller	set	
to	 37	 oC.	 Scans	 were	 taken	 periodically	 until	 no	 spectral	 change	 was	 observed.	
Triplicate	 measurements	 were	 obtained	 and	 curves	 were	 fit	 using	 one	 phase	
association	in	Prism	software.	
4.3	In	vitro;	GL002	with	Guanosine	by	Uv‐Vis	spectroscopy:	Experimental	
The	 reaction	kinetics	were	obtained	 for	GL002	with	guanosine	 (Alfa	Aesar,	





μL	 of	 6.55	mM	GL002	 (20	 μM)	was	 added	 to	 the	 cuvette	 and	 an	 initial	 scan	was	
taken.	The	sample	was	place	under	the	Dell	projector	(see	Chapter	3.1)	under	blue	
light	until	no	spectral	change	was	observed	and	photoejection	was	complete.	9	μL	of	
a	33.5	mM	guanosine	stock	 in	DMSO	was	added	 to	291	μL	of	 the	GL002/NaH2PO4	
buffered	solution	to	give	GL002:	guanosine:	NaH2PO4	concentrations	of	19.4	μM:	1	
mM:	 9.7	 μM	 respectively.	 The	 cuvette	 was	 placed	 in	 the	 sample	 holder	 with	 the	




















In	 vitro	 results	 indicate	 that	 the	 synthesized	 ruthenium	 complexes	 are	
capable	 of	 cross‐linking	 DNA	 when	 photo‐activated.	 In	 order	 to	 test	 their	 in	vivo	
activity,	 experiments	 were	 carried	 out	 on	 the	 A549	 cell	 line.	 A549	 or	
adenocarcinomic	 human	 alveolar	 basal	 epithelial	 cells	 are	 a	 non‐small	 cell	 lung	
cancer	cell	line.	These	adherent	cells	are	responsible	for	the	diffusion	of	water	and	
electrolytes	 across	 the	 alveoli	 of	 lungs	 and	 are	 cultured	 as	 a	 monolayer.	 	 The	
immortalized	 cell	 line	 was	 derived	 from	 an	 explanted	 tumor	 of	 a	 58‐year‐old	
Caucasian	 male.17	 The	 lung	 cancer	 cell	 line	 was	 chosen	 as	 a	 good	 model	 for	
photodynamic	 therapy	 as	 the	 lung	 is	 easily	 accessible	 with	 a	 light	 source	 and	
photodynamic	therapy	has	been	applied	with	success	to	lung	cancer.	18		
Chapter	5.1:	A549	Cytotoxicity	Assays	
Successful	photodynamic	 therapy	hinges	on	 the	ability	 to	provide	cytotoxic	
results	only	when	 the	 complexes	are	activated	with	 light.	As	described	 in	Chapter	
2.2,	multiple	complexes	have	been	synthesized	to	examine	cell	cytotoxicity	in	search	
of	 a	 good	 balance	 of	 light	 and	 dark	 toxicity.	 Due	 to	 the	 numerous	 compounds	
synthesized,	 this	 chapter	 will	 be	 divided	 and	 discussed	 as	 follows:	 1)	 by	 active	
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species	 a)	 (Ru(bpy)2	 and	b)	Ru(dmphen)2	 and	how	 the	 in	vivo	 A549	assay	 results	
relate	 to	structural	design	(see	Chapter	2	Design)	and	photo‐ejection	kinetics	 (see	




to	 relevant	 compounds	 discussed	will	 be	 included	 in	 the	 text	 and	 all	 cytotoxicity	
results	 will	 be	 summarized	 in	 a	 comprehensive	 table	 included	 at	 the	 end	 of	 the	
Chapter.	For	all	experiments,	cisplatin	was	used	as	a	non‐light	activated	control;	 it	




	 To	 test	 if	 only	 light	 activated	 complexes	 induced	 cytotoxicity,	 dark	 control	
experiments	were	 carried	 out	 to	 observe	 efficacy	 between	 the	 light	 activated	 and	
unactivated	 complexes.	 Cell	 viability	 was	 determined	 through	 an	 ATP	 luciferase	
assay	that	produces	luminescence	in	the	presence	of	ATP.		Detergent	lysis	was	used	




















GL002	 Ru(bpy)2dmbpy	 0.6	 250	 417	
GL003	 Ru(bpy)2dmdpq	 1.2	 250	 216	
GL006	 Ru(bpy)2	‐3,3’‐dmbpy	 30	 250	 8	
GL007	 Ru(bpy)2dmphen	 0.1	 8	 80	
GL008	 Ru(bpy)2bcds	 56.3	 64.5	 1.2	
GL010	 Ru(bpy)2dmdppz	 22	 47	 2.1	








	 It	 is	 expected	 that	 complexes	 with	 similar	 backbones	 producing	 the	 same	
active	species	should	have	similar	light	IC50	values.	However,	with	these	complexes	
sharing	 the	 similar	 backbone,	 correlations	 between	 the	 structure	 and	 ejection	
profiles	 and	 the	 in	 vitro	 results	 can	 loosely	 be	 drawn	 to	 explain	 the	 potency	
observed	 in	 the	 in	vivo	 A549	 assay.	 The	 general	 trend	 is	 that	 complexes	 that	 are	
slower	to	produce	the	active	species	are	less	effective	at	cross‐linking	DNA	and	are	
less	potent	compared	to	their	faster	ejecting	derivatives.	The	model	complex	GL002	
shows	the	 largest	phototherapeutic	ratio	 for	 this	group	of	complexes	of	417.	Light	
activation	 of	 the	 compound	 resulted	 in	 an	 IC50	 of	 0.6	 μM	while	 the	 non‐activated	
compound	induced	cytotoxicity	with	an	IC50	of	250	μM.	A	similar	ratio	is	observed	
with	GL003	(216),	which	has	an	IC50	of	1.2	μM	and	dark	unactivated	IC50	of	250	μM.	
The	 slight	 decrease	 in	 light	 toxicity	 of	 GL003	 is	 attributed	 to	 the	 slower	 ejection	
profile	of	60.9	minutes	(see	Table	3.1).	This	compliments	the	two‐fold	increases	in	











decreases	 the	 overall	 toxicity	 toward	 the	 cell	 line.	 This	 could	 be	 related	 to	 the	
electrostatic	 interaction	with	DNA,	 raising	both	 the	 light	 and	dark	 toxicity	 to	56.3	
and	64.5	μM	respectively.	This	compliments	the	in	vitro	results	as	well	(IC50	=	60	μM,	
see	 Table	 4.1),	 possibly	 indicating	 that	 the	 negatively	 charged	 ligand	 has	 a	
decreased	 affinity	 towards	 DNA.	 The	 addition	 of	 the	 bc	 ligand	 in	 complex	 GL014	
(see	Table	2.2)	has	the	opposite	effect,	decreasing	both	the	 light	and	dark	toxicity.	
This	complex	is	slow	to	eject	at	59.7	minutes	(see	Table	3.1),	but	fairly	potent	when	
light	 activated	 (2.4	 μM),	 and	 has	 considerably	 more	 dark	 toxicity	 resulting	 in	 a	
diminished	 phototherapeutic	 window	 of	 3.9.	 GL023	 incorporates	 a	 similar	 ligand	
and	has	considerable	dark	toxicity	(see	Table	5.2).	Diminished	potency	compared	to	
GL002	 after	 light	 activation	was	 observed	 for	 complexes	 GL006	 and	 GL010,	with	
IC50	values	of	30	and	22	μM	respectively,	despite	the	fact	that	they	produce	the	same	
active	species.	This	is	attributed	to	their	respective	slow	ejection	profiles	(t1/2	values	
of	 230	 and	 >6	 hrs	 respectively;	 see	 Table	 3.1).	 On	 average	 these	 complexes	 are	
approximately	150	times	slower	than	GL002	at	producing	the	active	species	capable	
of	cross‐linking	DNA.	As	shown	in	the	in	vitro	results,	GL006	has	an	IC50	of	30	μM	at	







For	 complexes	GL006	and	010,	 irradiation	 times	 appear	 to	 be	 very	 important.	 To	




A	 different	 approach	 was	 evaluated	 with	 complexes	 containing	 the	
























GL018	 Ru(dmphen)28HQ	 0.3	 0.3	 1	
GL019	 Ru(dmphen)22‐Me‐8HQ	 0.6	 1.2	 2	
GL022	 Ru(dmphen)2bpy	 1.2	 24.5	 20.4	
GL023	 Ru(dmphen)2bp	 0.2	 0.5	 2.5	
GL039	 Ru(dmphen)2dpq	 0.8	 49.4	 61.8	
	




but	 dark	 toxicity	 was	 sacrificed.	 These	 complexes	 have	 narrow	 phototherapeutic	
windows	 and	behave	 somewhat	 like	 traditional	 therapeutic	metal	 complexes.	 The	
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quinoline	 ligands	 alone	 are	 known	 cytotoxic	 agents	 and	 are	 discussed	 in	 Chapter	
2.1.19	GL018	and	019	were	synthesized	to	evaluate	the	phototherapeutic	ratio	of	the	
addition	 of	 these	 cytotoxic	 ligands	 with	 the	 strained	 backbone.	 On	 average,	 the	











experiments	 (Table	 4.1).	 Derivatives	 containing	 both	 of	 these	 ligands	 should	 be	
synthesized	with	negatively	charged	backbones	such	as	Ru(bpds)2	(see	Table	2.1)	to	
attempt	 to	 reduce	 the	 dark	 toxicity	 issues	 associated	 with	 these	 complexes.	 The	
complex	GL022	ejects	 in	a	timely	manner	(5.4	minutes,	see	Table	3.1)	and	ejects	a	
mixture	of	products	(see	Table	3.2).		With	this	combination	of	ligands,	dark	toxicity	






the	 in	 vitro	 gels	 (see	 Figure	 4.6).	 A	 control	 complex	 of	 Ru(bpy)2bp	 should	 be	
synthesized	 to	 observe	 the	 dark	 toxicity	 associated	 with	 the	 ligand.	 GL039	 has	 a	
wide	 phototherapeutic	 window	 of	 61.8	 and	 is	 quick	 to	 eject	 at	 3.2	 minutes	 (see	
Table	 3.1)	 producing	 one	 active	 species	 (Ru(dmphen)dpq,	 see	 Table	 3.2).	 This	
complex	 contains	 a	 planar,	 intercalating	 ligand	 that	 has	 a	 high	 affinity	 to	 DNA	 as	
seen	in	the	in	vitro	pUC19	results	at	three	hours	(IC50	=	15	μM,	see	Table	4.1).	A	light	
activated	 in	 vivo	 IC50	 value	 of	 0.8	 μM	 is	 attributed	 to	 the	 ejection	 of	 the	 single	





	 Several	 research	 groups	 are	 synthesizing	 complexes	 that	 produce	 single	




















GL004	 Ru(bpy)2phen	 40	 250	 6.3	
GL005	 Ru(bpds)2dmbpy	 1.3	 200	 154	
GL021	 Ru(bpy)2dpq	 123	 123	 1	
	
Figure	 5.4:	 Cytoxicity	 curves	 of	 example	 complexes	 that	 produce	 in	 vitro	 single	
strand	breaks	
	 	
	 Of	 these	 complexes,	 GL004	 is	most	 efficient	 at	 producing	 the	 in	vitro	 DNA	
breaks	 followed	 by	 GL021,	 and	 lastly	 GL005	 (15,	 30,	 and	 60	 μM	 respectively,	 see	
Table	 4.1).	 However,	 there	 is	 a	 disconnect	 in	 this	 design	 approach	 based	 on	 the	
efficiency	 to	 produce	 in	vitro	single	 strand	 breaks	 and	 A549	 cell	 cytotoxicity.	 The	
worst	 single	 strand	 breaker,	 GL005,	 is	 shown	 in	 Table	 5.3	 to	 produce	 the	 best	
phototherapeutic	window	of	154	(see	cytotoxicity	curve	in	Figure	5.5),	followed	by	
GL004	 (6.3)	 and	GL021	 (1).	 	 GL005	 is	 the	 only	 photoactive	 complex	 in	 the	 group	
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with	 a	 t1/2	 of	 0.6	 minutes	 (see	 Table	 3.1).	 This	 complex	 contains	 the	 Ru(bpds)2	
backbone	 and	 carries	 an	 overall	 charge	 of	 ‐2	 (see	 Table	 2.2),	 ejecting	 the	 dmbpy	
ligand	 upon	 light	 activation	 (see	 Table	 3.2).	 GL004	 contains	 the	 phen	 ligand	 (see	
Table	 2.1).	 This	 ligand	 is	 known	 to	 produce	 ROS,	 and	 a	 similar	 metal	 complex,	
Cu(phen)2,	 is	used	as	a	standard	to	produce	single	strand	breaks	in	the	 in	vitro	gel	
experiments	 (see	 Chapter	 4	 Experimental).2	 GL021	 has	 no	 distinguishable	
phototherapeutic	window	and	contains	an	intercalating	dpq	ligand	(see	Table	2.1).	
The	planar	nature	of	the	dpq	ligand	enhances	DNA	affinity	leading	to	dark	toxicity.5	
This	 complex	 intercalates	 as	 evident	 in	 the	 smearing	 of	 the	 DNA	 in	 the	 gel	 and	
shows	a	 fairly	efficient	 in	vitro	 IC50	of	30	μM	(see	Table	4.1)	 for	single	strand	DNA	
breaks.		Based	on	this	study,	designing	complexes	based	on	their	ability	to	produce	
single	 strand	 breaks	 does	 not	 correlate	 to	 in	vivo	cell	 cytotoxicity,	 at	 least	 in	 the	























GL005	 Ru(bpds)2dmphen	 1.3	 250	 154	
GL008	 Ru(bpy)2bcds		 56.3	 64.5	 1.2	
	







grasp	 an	 understanding	 of	 how	 the	 overall	 negative	 charge	 affects	 in	vivo	 results.	
Complex	GL008	has	a	net	0	charge,		a	t1/2	of	12.6	minutes	(see	Table	3.1),	and	ejects	
the	bcds	ligand	upon	light	activation	(see	Table	3.2),	producing	the	Ru(bpy)2	active	








unique	 approach	 for	 photodynamic	 therapy	 in	 that	 DNA	 affinity	 can	 possibly	 be	
reduced	 or	 gained	 based	 on	 electrostatics	 as	 well	 as	 structural	 features	 of	 the	
complex.	 To	 obtain	 DNA	 affinity,	 modifications	 to	 the	 structure	 should	 include	
intercalating	 ligands.	 Increased	 dark	 toxicity	 can	 also	 be	 obtained	 through	 the	
addition	 of	 bathophen	 or	 quinoline	 ligands	 and	 decreased	 dark	 toxicity	 can	 be	
achieved	 through	 addition	 of	 negatively	 charged	 ligands.	 These	 functionalities	
should	be	examined	in	future	works.	Complexes	displaying	a	red	shifted	absorption	
profile	 could	 improve	 the	 current	 PDT	 capabilities	 by	 penetrating	 deeper	 lying	
tumors.20	Derivatives	of	complexes	containing	ligands	that	display	cytotoxic	activity	
should	be	 coupled	with	 essentially	 inert	backbones.	The	 rich	nature	of	 ruthenium	



















GL001	 Cisplatin	 1.5	 1.5	 1	
GL002	 Ru(bpy)2dmbpy	 0.6	 250	 417	
GL003	 Ru(bpy)2dmdpq	 1.2	 250	 216	
GL004	 Ru(bpy)2phen	 40	 250	 6.3	
GL005	 Ru(bathophendisulfonate)2dmbpy	 1.3	 250	 192	
GL006	 Ru(bpy)2‐3,3’dmbpy	 30	 250	 8	
GL007	 Ru(bpy)2dmphen	 0.1	 8	 80	
GL008	 Ru(bpy)2bathocuprionedisulfonate	 56.3	 64.5	 1.2	
GL009	 Ru(bpy)2dppz	 22	 22	 1	
GL010	 Ru(bpy)2dmdppz	 22	 47	 2.1	




















GL013	 Ru(bpy)22,2’biq‐3,3’dca	 >300	 >300	 1	
GL014	 Ru(bpy)2bathocuprione	 2.4	 9.3	 3.9	
GL018	 Ru(dmphen)28HQ	 0.3	 0.3	 1	
GL019	 Ru(dmphen)2‐2Me8HQ	 0.6	 1.2	 2	
GL021	 Ru(bpy)2dpq	 123	 123	 1	
GL022	 Ru(dmphen)2bpy	 1.2	 24.5	 20.4	
GL023	 Ru(dmphen)2bathophen 0.2	 0.5	 2.5	
GL039	 Ru(dmphen)2dpq	 0.8	 49.4	 61.8	
	
Chapter	5.2:	In	Vivo	A549‐GSH	Cell	Viability	Assay	
The	A549	 lung	 cancer	 cell	 line	 chosen	 for	 this	work	 is	 known	 for	 elevated	
glutathione	(GSH)	levels.	A	seven‐fold	increase	was	found	in	the	A549	cell	line	when	
compared	 to	 normal	 human	 lung	 fibroblast	 cell	 line	 (CCL‐210).14	 Normal	 cellular	
levels	of	GSH	range	from	1‐30	mM13c	The	many	roles	GSH	plays	in	cellular	activity	
are	discussed	in	Chapter	4.4.	Detoxification	of	antineoplastic	agents	such	as	cisplatin	
is	 performed	 by	 glutathione	 S‐transferases	 that	 bind	 the	 metal	 and	 are	 removed	
106	
	
from	 the	 cell	 via	 the	 ATP	 dependent	 GS‐X	 pump.22	 Elevated	 levels	 of	 GSH	 hinder	
cytoxicity	 of	 various	 antineoplastic	 drugs	 like	 melphalan,	 nitrogen	 mustard,	 and	
cisplatin.14,23	 In	 addition	 to	 decreased	 cytotoxicity	 from	 these	 common	




GSH	 was	 performed	 where	 the	 amount	 of	 GSH	 was	 increased	 from	 0‐16	 mM	
followed	 by	 the	 addition	 of	 the	 cytotoxic	 complexes.	 Cisplatin	 and	 GL002	
concentrations	were	held	constant	at	20	μM.	The	IC50	of	cisplatin	in	the	absence	of	
GSH	was	 found	 to	 be	 1.5	 μM	 on	 A549	 cells	 (see	 Table	 5.5).	 	 Cisplatin	 results	 are	
shown	 in	 Figure	 5.6a	 and	 are	 consistent	 with	 the	 literature	 in	 that	 cell	 viability	
increases	with	 increasing	amounts	of	GSH.	Thus,	 cisplatin	becomes	a	 less	efficient	
cytotoxic	complex,	with	a	GSH	IC50	value	of	4.3	μM.	~100%	of	cells	are	viable	at	the	
top	GSH	concentration	of	16	mM.	
GL002	 was	 found	 to	 react	 minimally	 with	 GSH	 in	 dark	 experiments	 and	
slowly	 with	 GSH	 upon	 photo‐activation	 in	vitro,	 with	 a	 t1/2	=	 247.6	 minutes	 (see	
Figure	4.9b).	The	A549	IC50	value	for	the	activated	complex	GL002	is	0.6	μM	(Table	
5.5).	 Figure	 5.6b	 shows	 the	 GSH	 titration	with	 photoactivated	GL002.	 Glutathione	
seems	 to	 enhance	 cytotoxicity	with	 light	 activated	GL002.	No	 effect	was	observed	






evade	 detoxification	 by	 GSH	 while	 unactivated	 renders	 light	 activation	 of	 the	
complexes	 a	 viable	 PDT	 method.	 Similar	 in	 vitro	 pUC19	 gel	 experiments	 were	
carried	out	by	contributing	scientists	 in	our	 lab	with	similar	results.	Future	 in	vivo	
A549	light	activated	studies	should	be	performed	to	determine	the	amount	of	GSH	
required	 for	 the	 complete	 deactivation	 of	 photo‐activated	 GL002.	 	 These	 results	
indicate	 that	 the	ruthenium	PDT	strategy	does	not	suffer	 the	same	 inactivation	by	
biological	 thiols	as	platinum	agents	at	physiological	 concentrations	of	GSH.	Future	













Minimum	 Essential	 Medium	 (DMEM),	 with	 Earle’s	 Balanced	 salt	 solution	 (ATCC)	
supplemented	 with	 10%	 (v/v)	 Serum	 Supreme	 (Lonza,	 Biowhittaker)	 and	 1%	
Penicillin/	 Streptomycin	 (Gibco).	 	 Cells	were	maintained	 at	 37	 oC	 in	 a	 humidified	
atmosphere	of	95%	air	and	5%	CO2.	
All	compounds	were	screened	for	cytoxicity	in	the	absence	of	light	and	after	
light	 activation.	 Light	 and	 dark	 toxicity	 screens	 were	 carried	 out	 on	 cell	 passage	
numbers	between	7	and	15	in	96	well	plates	(Costar)	in	Optimem	I	Reduced	Serum	
Medium	 with	 1%	 Serum	 Supreme	 and	 1%	 Penicillin/	 Streptomycin	 (Gibco)	 in	
duplicate.	 	The	cells	were	seeded	in	the	96	well	plates	(50	μL)	at	a	density	of	1.5	x	
103	 cells	 per	 well	 and	were	 allowed	 to	 adhere	 for	 at	 least	 four	 hours	 before	 the	
addition	of	compound.	
600	 μM	 stock	 solutions	 of	 the	 ruthenium	 complexes	 were	 prepared	 in	
Optimem	with	1%	Serum	Supreme	on	a	separate	96	well	plate.		220	μL	were	added	
to	 all	 other	wells	 and	 1:3	 serial	 dilutions	were	 performed	by	 transferring	 110	 μL	





96	 well	 plate	 containing	 50	 μL	 of	 cells	 (1:2	 dilution)	 to	 give	 the	 final	 ruthenium	
concentrations:	300	μM,	100	μM,	33.5	μM,	11	μM,	3.7	μM,	1.2	μM,	0.4	μM,	and	0	μM.	
During	the	addition	of	the	ruthenium	complexes	to	the	cells,	care	was	taken	
to	protected	 the	 compounds	 from	 light.	After	 compound	addition,	 the	plates	were	
covered	with	aluminum	foil	to	continue	their	protection	from	light	and	incubated	at	
37	 oC	 with	 5%	 CO2	 in	 a	 humidified	 atmosphere	 for	 96	 hours.	 Cell	 viability	 was	
subsequently	measured	with	the	Cell	Titer‐Glo	Luminescent	Cell	Viability	Assay	Kit	
(Promega).	 Viability	 was	 measured	 using	 a	 Tecan	 Spectrafluor	 Plus	 plate	 reader	
equipped	 with	 Magellan	 v7.0	 software.	 The	 luminescent	 signal,	 due	 to	 the	
conversion	of	luciferin	and	ATP	to	oxyluciferin,	AMP,	and	light,	was	measured	after	a	
five	minute	incubation	of	the	cells	with	the	cell‐titer	glo.	During	this	time	complete	
cellular	 lysis	 occurred	 allowing	 for	 maximal	 signal	 with	 minimal	 well	 to	 well	
variability.	
Upon	 overnight	 incubation	 of	 the	 compounds	 in	 the	 absence	 of	 light,	 light	
activation	studies	were	carried	out	using	a	3M	overhead	projector	(model	955)	with	




measured	 with	 the	 aforementioned	 Promega	 Cell	 Titer‐Glo	 Luminescent	 Cell	
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